Reorganising specialist cancer surgery for the twenty-first century: a mixed methods evaluation (RESPECT-21). by Fulop, NJ et al.
STUDY PROTOCOL Open Access
Reorganising specialist cancer surgery for
the twenty-first century: a mixed methods
evaluation (RESPECT-21)
Naomi J. Fulop1*, Angus I. G. Ramsay1, Cecilia Vindrola-Padros1, Michael Aitchison2, Ruth J. Boaden3,
Veronica Brinton4, Caroline S. Clarke5, John Hines6,7, Rachael M. Hunter5, Claire Levermore 6, Satish B. Maddineni8,
Mariya Melnychuk1, Caroline M. Moore9, Muntzer M. Mughal6, Catherine Perry3, Kathy Pritchard-Jones6,
David C. Shackley8, Jonathan Vickers8 and Stephen Morris1
Abstract
Background: There are longstanding recommendations to centralise specialist healthcare services, citing the
potential to reduce variations in care and improve patient outcomes. Current activity to centralise specialist cancer
surgical services in two areas of England provides an opportunity to study the planning, implementation and
outcomes of such changes. London Cancer and Manchester Cancer are centralising specialist surgical pathways for
prostate, bladder, renal, and oesophago-gastric cancers, so that these services are provided in fewer hospitals. The
centralisations in London were implemented between November 2015 and April 2016, while implementation in
Manchester is anticipated in 2017.
Methods/Design: This mixed methods evaluation will analyse stakeholder preferences for centralisations; it will use
qualitative methods to analyse planning, implementation and sustainability of the centralisations (‘how and why?’);
and it will use a controlled before and after design to study the impact of centralisation on clinical processes,
clinical outcomes, cost-effectiveness and patient experience (‘what works and at what cost?’). The study will use a
framework developed in previous research on major system change in acute stroke services. A discrete choice
experiment will examine patient, public and professional preferences for centralisations of this kind. Qualitative
methods will include documentary analysis, stakeholder interviews and non-participant observations of meetings.
Quantitative methods will include analysis of local and national data on clinical processes, outcomes, costs and
National Cancer Patient Experience Survey data. Finally, we will hold a workshop for those involved in
centralisations of specialist services in other settings to discuss how these lessons might apply more widely.
Discussion: This multi-site study will address gaps in the evidence on stakeholder preferences for centralisations of
specialist cancer surgery and the processes, impact and cost-effectiveness of changes of this kind. With increasing
drives to centralise specialist services, lessons from this study will be of value to those who commission, organise
and manage cancer services, as well as services for other conditions and in other settings. The study will face
challenges in terms of recruitment, the retrospective analysis of some of the changes, the distinction between
primary and secondary outcome measures, and obtaining information on the resources spent on the
reconfiguration.
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Background
Centralising services to improve quality of care and
patient outcomes
There are longstanding recommendations in the English
National Health Service (NHS) and internationally to
centralise specialist services [1–5]. Recent guidance in
the English NHS indicates that centralising specialist
services will remain a priority in the future [6, 7]. Cen-
tralisation has potential to improve care provision and
patient outcomes by increasing the likelihood of patients
being treated in hospitals that have a full range of expe-
rienced specialists and equipment to support care
provision. For instance, recent research indicates that
centralising acute stroke services into fewer high-volume
units is associated with significantly better provision of
evidence-based clinical interventions [8] and signifi-
cantly greater reductions in patient mortality [9]. How-
ever, little is known about processes by which services
are centralised, the impact of changes on patients and
staff, and factors influencing implementation [10].
Centralising cancer services
Recent research indicates that there is limited evidence
of the cost impact of centralising cancer services [10, 11]
and patient, public and professional preferences in rela-
tion to centralisations of this kind [12, 13]. High volume
is associated with better outcomes in specialist surgery
for OG cancers [14] and urological cancers [15]. How-
ever, the strength of this relationship varies between spe-
cialties [16]. Furthermore, centralising cancer services
may place increased travel demands on patients and
families and may limit people’s access to quality care
[17]. A review of evidence indicates that willingness to
travel for specialist care is greater if a hospital has a
good reputation, if the condition is serious or urgent
and if the patient is of a higher socioeconomic status;
willingness to travel further is lower amongst older pa-
tients and frequent users of services, and preferences
vary according to the length of the journey [18, 19].
Specialist surgical services for urological and oesophago-
gastric cancers in London Cancer and Manchester Cancer
Networked cancer systems London Cancer (covering the
geographical areas of North Central London, North East
London, and West Essex (population 3.2 million)) and
Manchester Cancer (covering Greater Manchester and
East Cheshire (population 3.1 million)) have been work-
ing towards centralising specialist surgery services for a
number of cancers [20, 21]. This study will evaluate four
of the surgical cancer pathways that are being centra-
lised in both areas: prostate, renal, bladder and
oesophago-gastric (OG) cancers. There are over 60,000
new cases of these cancers in the UK every year [22–25].
Prostate cancer is the second highest cause of cancer
deaths in men [23]. Five-year survival rates are 85% for
prostate cancer [26], 50–60% for bladder and renal can-
cers [22, 24], 12% for oesophageal cancer and 16% for
gastric cancer [3].
Pre-centralisation pathways
In both areas, pre-centralisation, potential cancer patients
were referred to their local cancer centre for diagnosis,
and either remained there for treatment or were referred
to a specialist centre; protocols for referral to specialist
centres varied across referring sites. The range of treat-
ment available to patients (e.g. access to robotic surgery
for prostate and bladder patients; access to specialist sur-
geon for renal and OG patients; degree of subspecialisa-
tion of urological surgeons) varied significantly between
specialist centres, as did patient volumes (Fig. 1a).
Centralisations in London Cancer and Manchester Cancer
London Cancer and Manchester Cancer have proposed
that specialist surgical services for each of these cancers
should be centralised into fewer specialist centres (Table 1),
with standardised patient pathways, with the aim of redu-
cing variations in care. It is anticipated that increased pa-
tient volumes in specialist centres will allow greater
specialisation of staff and greater experience and expertise
across teams working in those centres [27, 28]. Further, spe-
cialist centres will offer a full range of surgical technologies
(e.g. robotics) and equal access to innovative techniques, in-
cluding less invasive surgical procedures and non-surgical
procedures (such as radiotherapy, brachytherapy and hor-
mone therapy) [27, 29]. These centralisations are being
conducted within a wider context of change, impacting on
specialist services for other cancers and other health condi-
tions, e.g. cardiac services. In some cases, the changes build
on previous activity to centralise specialist cancer surgery
into a smaller number of services.
Post-centralisation, local units will continue to provide
much patient care, including diagnosis, ongoing radio-
therapy, chemotherapy and some forms of non-complex
surgery. In addition, it is planned that they will have
closer involvement with specialist centres, with the aim
of improving quality of care across the whole system,
through participation in specialist multidisciplinary
teams (SMDTs), and specialists providing training and
delivering some outpatient care. Both sets of proposals
emphasise the importance of continuity of care for pa-
tients (in relation to coordination of care and ongoing
contact with patients across different services over time),
for example by the specialist centre hosting follow-up
clinics and joint appointments in local units [20, 21].
Current status of centralisations
Implementation of the London Cancer centralisations
was completed over the period November 2015 to April
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2016. Implementation of the Manchester Cancer centra-
lisations is planned for 2017.
Conceptual framework
The study will use a framework developed as part of a
study of major system change in acute stroke services and
designed to be applicable in various clinical settings [30,
31] (Fig. 2). In this study, we will further develop this
framework in a different healthcare context; in addition,
as the centralisations have been led by networked systems,
we will consider how networks influence major system
change. Our framework presents key processes of major
system change and the relationships between them: the
decision to change (C1) (drivers for change, and how the
decision to change is led and governed, e.g. the import-
ance of combining ‘bottom up’ clinical leadership with
‘top down’ central leadership, the impact of social and pol-
itical context [32, 33] and the role played by clinical
leaders in sharing knowledge and driving change across
networks [34, 35]); developing and agreeing new service
models (C2) (e.g. clinicians working across organisational
boundaries to develop service specifications) [32, 36, 37];
how changes are implemented (C3) (e.g. the degree to
which implementation is phased, the level of hands-on
Fig. 1 Simplified models summarising specialist cancer surgery—(1a) before and (1b) after centralisation
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facilitation and ways in which knowledge is shared across
organisational and professional boundaries) [32, 36–38];
adherence to the new model (C4) (including factors that
might influence fidelity to the new pathways, e.g. pathway
complexity and organisational boundaries) [33, 37, 38].
This evaluation was peer reviewed by the National In-
stitute for Health Research Health Services and Delivery
Research (NIHR HS&DR) Programme prior to being
funded (project ref 14/46/19) and received ethical ap-
proval in July 2015 from the Proportionate Review Sub-
committee of the NRES Committee Yorkshire and the
Humber—Leeds (reference 15/YH/0359).
Study aim, research questions
This study aims to analyse centralisation of specialist
cancer surgery services in two areas of England (cov-
ered by London Cancer and Manchester Cancer) and
identify lessons to inform centralisation in other health-
care settings. It will address the following research
questions:
1. What are patient, public and professional
preferences in relation to these centralisations?
2. What were the key processes in centralising
specialist cancer surgery services in the two regions?
3. What is the impact of the centralisations on staff
and healthcare provider organisations, including
ways of working, skill mix and approaches to
collaboration?
4. What is the impact on provision of care, in terms of
clinical processes and outcomes?
Fig. 2 Conceptual framework: key components of major system change [31]
Table 1 Overview of services providing specialist surgery: mean
number of cases per year, number requiring complex surgery
per year and number of specialist centres pre- and post-
centralisation (2015)
Cancer London Cancer Manchester Cancer
Total
cases
Require
surgery
Specialist
centres
Total
cases
Require
surgery
Specialist
centres
Before After Before After
Bladder 372 130 2 1 628 113 5 ↓
Prostate 1600 220 2 1 1879 283 5 ↓
Renal 282 190 9 1 407 269 5 ↓
OG 566 129 3 2 868 152 3 ↓
London Cancer figures [20, 25]; Manchester Cancer figures [21, 25]; number of
post-centralisation centres in Manchester Cancer still to be confirmed
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5. What is the impact on patient experience, including
choice and continuity of care?
6. What is the cost and cost-effectiveness of the
changes?
7. How might lessons from centralising specialist
cancer surgery services be applied in future
centralisations of specialist cancer services and other
specialist settings?
Methods/Design
Design
This is a multi-site, contemporaneous study of the cen-
tralisation of specialist surgical pathways for four cancers
in two large conurbations in England. To understand
stakeholder preferences for the organisation of cancer
specialist surgical services, a discrete choice experiment
will be conducted; to analyse the centralisations, we will
combine quantitative analysis of the impact of centralisa-
tion on clinical processes, clinical outcomes, cost-
effectiveness and patient experience (‘what works and at
what cost?’), with qualitative analysis of their develop-
ment, implementation and sustainability (‘how and
why?’); a similar approach was used previously in a study
of major system change in acute stroke services [30].
The study will focus on four surgical pathways (for
prostate, bladder, renal and OG cancers). These path-
ways have been selected because they are being cen-
tralised in both areas, facilitating analysis of how
changes occur in different contexts. The study will
also analyse different degrees of centralisation, as the
reduction in number of specialist centres varies sig-
nificantly (see Table 1).
Understanding stakeholder preferences
We will conduct a discrete choice experiment (DCE)
[39–41] to examine stakeholder (patients, the public,
healthcare professionals) preferences for centralisation,
in relation to such attributes as travel time to hospital to
undergo surgery, and risk of serious complications.
Understanding implementation and sustainability
We will use documentary analysis, stakeholder inter-
views and non-participant observations to identify
drivers for change; how the centralisations were planned
and implemented and factors influencing this; the extent
to which the proposals were implemented; and factors
influencing sustainability of the changes.
Understanding what works and at what cost
This component of the evaluation will use a controlled be-
fore and after design. The centralisations will be analysed in
terms of the extent to which changes were implemented
and the impact of centralisation on care provision, clinical
outcomes, patient experience and cost-effectiveness.
Exploring generalisability to other contexts
To develop lessons that might support centralisation in
other contexts, we will host a workshop for stakeholders
involved in planning centralisations of specialist cancer
services elsewhere and other types of specialist service.
Stakeholders will include providers, commissioners and
patients and patient groups from across the country.
Working with attendees, we will identify factors influen-
cing generalisability of our findings and develop lessons
that will be of use in different settings.
Sampling
Discrete choice experiment
The DCE will elicit preferences for how services are
organised from three stakeholder groups: patients, the
public and healthcare professionals. Each stakeholder
group will sample London, Greater Manchester and
elsewhere in England. Sample size calculations for
DCEs are not straightforward but a sample size of 300
is commonly recommended [42]. Our sample size will
be 400:200 patients with prostate, bladder, renal and
OG cancers, (25% for each cancer); 100 healthcare pro-
fessionals involved in managing these cancers; and 100
members of the public (anyone who is neither a cancer
patient nor a healthcare professional).
Documentary analysis, stakeholder interviews and non-
participant observations
We will collect documents covering development, planning
and implementation of the centralisations. We will also col-
lect documents on contextual factors, including policy and
media coverage. Documents will be collected from 2006,
when the Royal College of Surgeons of England launched a
consultation on centralisation of surgical services [43].
We will sample up to 200 stakeholder interviewees
purposively across London Cancer and Manchester
Cancer (Fig. 3). Participants will include people involved
with governance of the centralisations (e.g. programme
boards, local commissioners and patient representative
groups). For each cancer pathway, we will interview cli-
nicians and managers in a specialist centre, a local unit
and a service no longer providing specialist surgical
care.
Researchers will observe activities related to planning,
implementation and ongoing governance of the centra-
lised services, for example pathway board meetings,
multidisciplinary team meetings and training events.
Impact on clinical processes, outcomes and patient
experience
Table 2 summarises the data we will analyse and Table 3
the key variables.
The outcomes denoted as primary in Table 3 were se-
lected with clinical collaborators to enable sample size
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calculations to demonstrate the feasibility of the quanti-
tative analysis. However, we note that selecting a single
measure as being of primary importance in a mixed
methods evaluation of a complex intervention is diffi-
cult, as a range of outcomes is likely to be important to
stakeholders. Consequently, our study will analyse a
range of outcome measures and consider the distinction
between ‘primary’ and ‘secondary’ measures to be some-
what arbitrary.
For prostate cancer, we need a sample size of 1074
patients comprising 119 in the exposed group (London
Cancer and Manchester Cancer post-reconfiguration)
and 955 in the unexposed group (rest of England plus
London Cancer and Manchester Cancer pre-
reconfiguration) to have an 80% chance of detecting,
as significant at the 5% level, an increase in the pro-
portion of men treated by primary surgery who are
continent at 12 months from 80 to 90% assuming an
enrolment ratio of 8:1 (http://clincalc.com/stats/sam-
plesize.aspx [26 September 2016]). For bladder, renal
and OG cancers, we need a sample size of 4446 pa-
tients (494 in the exposed group) for the same statis-
tical power and enrolment ratio as above to detect a
decrease in 30-day post-operative mortality from 2 to
1%. Based on the figures in Table 2, we expect our
datasets to contain information on primary outcomes
for approximately the following number of patients
per year: prostate cancer, 1300; bladder cancer, 1400;
renal cancer, 6000; OG cancer, 2000. For each cancer,
we will have at least 4 years of data (2014–2017), sug-
gesting that the required sample sizes are feasible.
Cost-effectiveness
Collaborating with providers and commissioners, we will
obtain information on the costs associated with planning
and implementing the centralisations. Some of these costs
are likely to represent one-off, sunk costs to providers and
commissioners, and will be important in informing other
organisations about potential cost of centralisation. We
will obtain data regarding outcomes of surgery pre- and
post-centralisation to allow us to quantify any impact on
cost per procedure and in-patient hospital costs that may
occur as a result of centralisation, for example from
changes in patient case-mix and complexity, changes in
bed management practices or how theatres are booked
and used. The cost-effectiveness of the centralisations will
be reported as incremental cost per quality-adjusted life-
year gained and incremental cost per change in outcome.
The outcome(s) included in the latter will be those listed
in Table 2 plus others informed by the DCE ranking re-
sults, for example if stakeholders indicate a clear prefer-
ence for more than one outcome, a separate analysis will
be performed for each.
Fig. 3 Anticipated interviewee recruitment per area
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Data collection
Discrete choice experiment
We will develop a questionnaire that elicits stakeholder
preferences for the reorganisation of cancer surgical ser-
vices. The questionnaire will present choices between op-
tions differing on a number of attributes that may be
affected by centralisation, for example travel time to hos-
pital for surgery, number of operations the centre conducts
annually and the risk of serious complications from surgery.
We will identify attributes by reviewing the literature and
consulting with patients, the public and professionals. Attri-
bute descriptions will undergo review by the Plain English
Campaign. Once identified, we will determine plausible
levels of each attribute based on clinically feasible ranges
derived from systematic literature reviews, planning docu-
ments, audit reports, NICE guidelines, published studies
and consultations with healthcare professionals.
To design the questionnaire, we will use a pairwise
choice framework and compile a set of pairwise scenar-
ios that describe feasible combinations of levels and
Table 2 Summary of datasets
Dataset Year change
occurs
Years
sampled
Mean number of patients
per year, by area
Notes
Prostate cancer
National Prostate
Cancer Audit
2015 2014–2017 Incidence of prostate cancer:
London Cancer = 1600
Manchester Cancer = 1879
Rest of England = 30,637
Audit commenced 2014
Mean annual incidence of prostate cancer
from UK Cancer Atlas data 2008–2010 [25]
True NTH
UK—post surgical
follow-up
2015 2014–2017 London Cancer = 500
Manchester Cancer = 300
Rest of England = 500
Estimated figures from co-author CMM
(True NTH UK—post surgical follow-up project lead)
National Cancer
Patient Experience
Survey
2015 2014–2017 London Cancer = 276
Manchester Cancer = 307
Rest of England = 5002
National Cancer Patient Experience Survey (2013) [65]
BAUS Radical
prostatectomy
dataset
2015 2014–2017 BAUS audit participation
(national) = 2093
BAUS Radical Prostatectomy Audit report (2012) [66]
Bladder cancer
Hospital episode
statistics
2015 2014–2017 Patients undergoing cystectomy
(national) = 1360
Incidence of bladder cancer:
London Cancer = 628
Manchester Cancer = 372
Rest of England = 7895
From NCIN analysis of 2005–2007 bladder cystectomies
Mean annual incidence of bladder cancer from UK Cancer Atlas
data 2008–2010 [25, 67]
National Cancer
Patient Experience
Survey
2015 2014–2017 London Cancer = 321
Manchester Cancer = 410
Rest of England = 6327
National Cancer Patient Experience survey (2013) [65] NB these
are overall figures for urological cancers—will be disaggregated
by ICD10 code.
Renal cancer
BAUS audit of
nephrectomies
2015 2014–2017 BAUS audit participation = 5851
Incidence of renal cancer:
London Cancer = 282
Manchester Cancer = 407
Rest of England = 5930
From BAUS nephrectomy audit report (2012)
Mean annual incidence of renal cancer from
UK Cancer Atlas data 2008–2010 [25]
National Cancer
Patient Experience
Survey
2015 2014–2017 London Cancer = 321
Manchester Cancer = 410
Rest of England = 6327
National Cancer Patient Experience survey (2013) [65]
NB these are overall figures for urological cancers – will be
disaggregated by ICD10 code.
OG cancer
AUGIS national
audit
2015 2014–2017 Patients undergoing
oesophagectomy and
gastrectomy (England) = 1967
Incidence of OG cancer:
London Cancer = 868
Manchester Cancer = 566
Rest of England = 11529
From AUGIS OG audit report (2013)
Mean annual incidence of OG cancer from UK Cancer
Atlas data 2008–2010 [25, 68]
National Cancer
Patient Experience
Survey
2015 2014–2017 London Cancer = 221
Manchester Cancer = 202
Rest of England = 3860
National Cancer Patient Experience survey (2013) [65]
NB these are overall figures for upper GI cancers – will be
disaggregated by ICD10 code.
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attributes of centralised versus non-centralised cancer
surgery services. The number of pairwise choices will be
reduced to a practical number for participants to answer
(eight questions per participant) using an algorithm that
maximises the efficiency of the experimental design [44].
The questionnaire will undergo plain English review and
will be piloted with patient representatives.
Quality Health (an organisation specialising in conduct-
ing surveys in healthcare settings, including the National
Cancer Patient Experience Survey (NCPES)) will assist in
the distribution and will be in charge of data collection,
data entry and preparation of the dataset. All data collected
will be anonymised, and demographic details will be cate-
gorised so that participants cannot be identified.
Documents, stakeholder interviews and non-participant
observations
Documentation covering planning, implementation and
impact of the centralisations will be obtained from staff
in Manchester Cancer, London Cancer and participating
provider and commissioning organisations. We will also
conduct online searches for further local and national
documentation, including relevant policy, guidance and
media reports.
Interview topic guides will be developed in collabor-
ation with patient and clinical members of the research
team to focus on key aspects of the centralisations, in-
cluding the decision to change, planning and implement-
ing the changes, perceived impact and sustainability of
changes and influential factors (e.g. local and national
contexts). Interviews will be digitally recorded for pro-
fessional transcription.
Non-participant observations will focus on record-
ing decision-making processes, the stakeholders who
are involved and not involved in planning and imple-
mentation, and influential contextual factors. Observa-
tions will be recorded as field notes. All interview
and observation data will be stored securely and
anonymised.
Impact on clinical processes, clinical outcomes and patient
experience
We will formally request data from the relevant organi-
sations (Table 2).
Table 3 Summary of primary and secondary outcomes, process
measures, mediating factors and required sample sizes for each
cancer
Prostate cancer
Primary
outcome
• Radical prostatectomy: proportion of men treated by
primary surgery who remain continent (pad free) at
12 months (research indicates range of 80–92%,
depending on procedure) [69]
Secondary
outcomes
• Radical prostatectomy: proportion of men treated by
surgery with pre-operative erectile function who
have erections sufficient for penetration at
12 months
• Length of stay
• Readmission
• Surgical complications
• Post-operative complications
• Diagnostic outcomes: proportion of men diagnosed
with clinically significant prostate cancer
• Patient experience, including choice of treatment,
access to services, confidence in staff,
communication, effectiveness of teamwork and
opportunity to participate in research
Bladder cancer
Primary
outcome
• 30-day post-operative mortality (national figure
(2012) = 2.4%) [70]
Secondary
outcomes
• Length of stay
• Proportion of patients offered neo-bladder
reconstruction
• Proportion of patients receiving neo-bladder
reconstruction
• Surgical complications (measured by Clavien–Dindo
grading)
• Patient experience (measures as above)
Renal cancer
Primary
outcome
• 30-day post-operative mortality (anticipated
figure = 0.9%) [71]
Secondary
outcomes
• 30 day readmission
• % of cases of T1a tumours having nephron-sparing
surgery
• Length of stay
• Surgical complications (measured by Clavien–Dindo
grading)
• Conversion from laparoscopic (including robotically
assisted) to open surgery
• Patient experience (measures as above)
OG cancer
Primary
outcome
• 30-day post-operative mortality (national figure
(2013) = 2.3%) [72]
Secondary
outcomes
• % of patients offered endoscopic resection for
tumours staged as T1a
• Length of stay
• % Complete R0 resection (i.e. full removal of tumour)
• Surgical complications—anastomotic leak
• Patient experience (measures as above)
Intermediate outcomes (all)
• Waiting times (within 62 days of referral, 31 days of
decision to treat)
• Number of patients seen by surgeon
• Case volume per surgeon
• Proportion of cases where surgery is an emergency
procedure
Mediating factors (all)
Table 3 Summary of primary and secondary outcomes, process
measures, mediating factors and required sample sizes for each
cancer (Continued)
• Patient characteristics (age, gender, ethnicity,
socioeconomic status)
• Cancer stage
• Whether procedure is a salvage procedure
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Cost-effectiveness
To populate the cost-effectiveness models, we will use
clinical process, clinical outcomes and patient experi-
ence data, along with data from published sources
including:
 Probabilities of disease progression (obtained from
systematically reviewing epidemiological and other
literature);
 Unit costs of healthcare resources used, including
professionals’ time (obtained from NHS reference costs
[45], previous studies [46], British National Formulary
[47], unit costs of Health and Social Care [48]);
 Health state utilities (obtained from the Cost-
Effectiveness Analysis Registry) [49].
Recruitment
Discrete choice experiment
The questionnaire will be distributed with a cover letter
and participant information sheet: these make clear that
consent is implied by participation in the survey.
Quality Health will use the NCPES database to identify
cancer patients who have agreed to take part in research.
A sample of these patients will be sent the questionnaire
and study information by post and invited to return the
questionnaire by post or complete it online.
Quality Health will recruit members of the public by
advertising the survey through health-related charities’
websites, newsletters, and mailing lists. Advertisements
will include a link to the online questionnaire and study
information.
To recruit healthcare professionals, the research team
will advertise the study through websites, newsletters
and mailing lists of relevant groups and organisations in
London, Greater Manchester and nationwide. Advertise-
ments will include a link to the online questionnaire and
study information.
Stakeholder interviews and non-participant observations
Study researchers will approach potential interviewees
and share study information via e-mail and telephone.
Potential interviewees will have at least 48 h to consider
participating and ask any questions about the research.
Interviews will be conducted only with written, fully in-
formed consent. Participants will be free to withdraw at
any time.
Permission to observe meetings will be obtained from
the Chair in advance. Participant information sheets will
be circulated with meeting papers to all members. On
first attendance, researchers will inform members about
the study, what participation entails, and that members
may decline to participate at any time. At subsequent
meetings, the researcher will announce him/herself as a
non-participant observer; agreement for observation to
proceed will be recorded in meeting minutes. If partici-
pants do not agree to participate, any contributions they
make to the meeting will be excluded from field notes; if
more appropriate, the researcher will withdraw from the
meeting.
Ward observations will only be conducted with per-
mission from clinical staff. Before commencing observa-
tions, researchers will attend meetings to discuss the
study and obtain staff consent. Patients will not be re-
cruited because researchers will not directly observe pa-
tients, but rather staff activity as patients pass through
cancer services. Posters explaining the purpose of the
observations will be displayed in participating clinical
areas, and copies of information sheets will be available.
During observations, researchers will be clearly identi-
fied with a badge, and will announce their presence.
Combining methods
Research strands will be combined throughout the life-
span of the study. In relation to data collection, interview
topic guides will be informed initially by the documentary
analysis and primary measures used in the quantitative
analyses; later topic guides will incorporate findings from
these analyses. Our document inventory will be structured
to facilitate the cost-effectiveness analysis. The process
and outcome analyses will in part be guided by documen-
tary analysis (e.g. identifying the ‘before’ and ‘after’ periods
of centralisations). Potential sources of cost data will be
partly identified through interviews and documentary ana-
lysis (e.g. relating to staffing and resource use), while the
focus of the cost-effectiveness analysis will be guided by
the results of the outcomes analysis and DCE.
Data analysis
Discrete choice experiment
We will summarise respondents’ rankings of attributes
descriptively and compare these between the three
stakeholder subgroups, testing for differences using rank
correlation coefficients. We will analyse preference data
using conditional logistic regression analysis. Attributes
measured on a continuous scale will be mean-centred;
attributes measured as categorical variables will be ef-
fects coded. The regression analysis will indicate relative
importance of attributes to respondents. Data will be
analysed for all respondents jointly and disaggregated by
the three stakeholder subgroups, controlling for available
baseline demographic characteristics. To explore trade-
offs participants make between attributes, we will calcu-
late the marginal rates of substitution (MRS), calculated
as a ratio of the coefficients of two attributes. The MRS
allows direct assessment of how much of one attribute
respondents are willing to trade for one unit of another
attribute and enables comparison of different attributes
on a common scale [50].
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We will use the regression results to calculate the pre-
dicted probability that different combinations of attri-
bute levels used in the experiment would be selected.
This allows us to rank centralised versus non-centralised
services in terms of their order of preference by respon-
dents [50] and to explore how this ranking varies by
stakeholder group.
Documentary analysis, stakeholder interviews and non-
participant observations
The documentary analysis will draw on our conceptual
framework (Fig. 2), reflecting key processes of change
and influential factors (e.g. governance structure, local
and national context). The data from the documentary
analysis will contribute to the development of detailed
timelines and narrative summaries of the centralisations.
Ongoing and iterative thematic analysis of interview
and observation data will be conducted, following estab-
lished procedures of constant comparative analysis [51].
Initial analysis and category building will include cat-
egory mapping and constant comparison. A subgroup of
co-investigators with qualitative expertise will develop
the analysis; and the whole research team will contribute
to interpretation of findings. Validity will be assessed in
relation to Patton’s four criteria of validity in qualitative
research: verification, rival explanations, negative cases
and triangulation [52].
Impact on clinical processes, clinical outcomes and patient
experience
We will aggregate risk-adjusted patient level data by Trust
and time (quarter) and use between-region difference-in-
differences regression analysis to investigate the impact of
the centralisations on clinical processes, clinical outcomes
and patient experience.
We will risk-adjust the observed patient outcomes using
expected outcomes that are obtained from patient level re-
gression models. For the primary outcomes, which are
binary, we will use logistic regression to regress each out-
come against a series of covariates including: gender; age;
interactions between age and gender; cancer diagnosis;
Charlson comorbidity index [53]; presence of 16 comor-
bidities included in the Charlson comorbidity index; eth-
nic group; deprivation quintile based on area of residence
[54]; and rural-urban classification based on area of resi-
dence [55]. The patient level regressions will be run only
on patients who had surgery before the reorganisations so
the risk adjustment will not be contaminated by the
changes. The regression coefficients will be used to predict
the probability of the outcome for every patient, in both
pre- and post-implementation periods. These will be ag-
gregated to create a dataset of the actual outcomes (actual
percentage of patients who were pad free at 12 months or
who had died by 30 days) and the expected outcomes, by
admitting hospital and quarter (from the logistic
regressions).
For each outcome and type of cancer, we will con-
struct a Trust-by-quarter dataset covering the whole of
England where possible containing data on clinical out-
comes and care processes plus covariates. We will re-
gress the risk-adjusted outcomes, measured at the Trust
level in each quarter, against a variable denoting cancer
surgery service centralisations, controlling for Trust and
time fixed effects. For the aggregate data the regression
model is
yjt ¼ α1 þ uj þ vt þ δ1D1jtD2jt þ ejt
where y is the risk-adjusted outcome of interest (mortal-
ity, readmissions, LOS; actual minus expected values), j
indicates Trust, t indicates quarter, α is a constant term,
u represents Trust fixed effects and v represents time
(quarter) fixed effects. D1 is a variable taking the value 1
if the provider Trust is in London Cancer/Manchester
Cancer and 0 otherwise; D2 is a variable which equals 1
if the observation belongs to the time period after the
centralisation and 0 otherwise. Sample weights based on
patient numbers in each Trust/quarter will be used. We
are interested in the sign and statistical significance of
the coefficient δ1, which quantifies the changes in risk-
adjusted outcomes over time in London Cancer and
Manchester Cancer controlling for the changes over
time in the rest of England. We will rerun the analysis
using outcomes that are not risk-adjusted at the first
stage as a sensitivity analysis. We will run pre-trend tests
to examine whether the outcomes had a different linear
trend in London Cancer and Manchester Cancer com-
pared with the rest of England before the centralisations.
This two-stage approach (patient level risk adjustment
followed by between-region difference-in-differences
analysis on aggregate Trust-by-quarter data) is consistent
with Medical Research Council guidelines for using nat-
ural experiments to evaluate population health interven-
tions [56] and has been used in previous studies [8, 57].
We will repeat the above analysis for the secondary
outcomes. The regression model used at the first stage
will reflect the functional form of the outcome measure,
for example: most of the outcomes are binary measures
so we will use logistic regression as described for the pri-
mary analysis; length of stay will be analysed using a
generalised linear model with gamma family and log link
to account for data skewness [58].
We will undertake a secondary analysis using synthetic
controls [59–62], defining a control group closely resem-
bling regions in which centralisation occurred in terms
of the outcomes in the period before the centralisations.
The synthetic controls will use a weighted combination
of Trusts from the rest of England to approximate pre-
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centralisation outcomes in London Cancer and Man-
chester Cancer. Trends in outcomes in London Cancer,
Manchester Cancer and their synthetic controls will then
be compared over time using an adapted version of the
regression model described above.
We will also use patient level regression analysis to re-
late the intermediate outcomes to the clinical outcomes.
We will regress the outcomes against the care processes,
the latter being included separately in individual models,
and all together in a single model. In these models, we
will control for gender, age, interactions between age
and gender, cancer diagnosis, Charlson comorbidity
index, presence of comorbidities, ethnic group,
deprivation and rural-urban classification.
Cost-effectiveness
We will construct cost-effectiveness models to test
whether centralisations reflect good value for money
30 days and 1 year post-surgery. Before and after deci-
sion analytic models will be constructed, with a different
model for each type of surgical cancer centralisation per
region. Where possible, we will construct a decision ana-
lytic model of an urban region in England that has not
been centralised as a control, using the synthetic con-
trols described above. The models will be used to calcu-
late NHS and personal social service costs and outcomes
of surgery pre- and post-centralisation, providing policy
makers, commissioners and providers with information
regarding value for money of centralising specialist
cancer surgical services. We will include information
and descriptive statistics on surgery, in-patient stay,
follow-up, readmission, centralisation and implementation
resource use and costs. We will report any costs available
from providers or commissioners. If this information is
not available, national published sources will be used.
Special attention will be paid to analysis of fixed and vari-
able costs and where assets have been purchased versus
staff costs, to ensure an accurate mean cost per patient.
Outcomes will be modelled as quality-adjusted life-
years (QALYs). We will assess the feasibility of calculat-
ing QALYs from patient-reported and clinical outcome
measures and, if this is not forthcoming, utility scores
for calculating QALYs will be obtained from the CEA
registry [56]. Cost-effectiveness will be calculated as the
mean cost difference of centralisation (after minus be-
fore), divided by mean difference in outcomes, to give
incremental cost-effectiveness ratios [63]. In addition to
reporting the mean incremental costs per QALY gained,
we will report the mean incremental cost per change in
outcome for each cost-effectiveness model performed
using outcome(s) chosen based on the DCE ranking re-
sults. We will conduct deterministic and probabilistic
sensitivity analyses to explore effects of uncertainty and
the effects of using national versus local values from
providers or commissioners [64]. Cost-effectiveness ac-
ceptability curves will be created comparing the net
monetary benefit (willingness to pay for the change in
outcome, minus the incremental cost), for each of the
centralisation options. We will assess the feasibility of
constructing before and after life-time models for each
cancer centralisation, extrapolating the results of survival
and readmission data described above. We will also as-
sess the feasibility of calculating the cost to primary care
of the different centralisation models. However, this is
unlikely to be viable, owing both to issues associated
with accessing the necessary data, and to the additional
resources that would be required to collect this
information.
Data synthesis
Studying centralisation of four pathways across two
areas allows development and testing of theories on how
change processes interact with the context in which they
take place. A multiple case study approach—in this
case, the governance of the Manchester Cancer and
London Cancer centralisations, and their implementa-
tion and impact within services—allows the analysis
of different organisational contexts and different degrees
of centralisation. We will combine findings from different
study components to test and further develop our concep-
tual framework (Fig. 2); in particular, we will provide
evidence on ways in which clinically-led networks con-
tribute to major system change in complex organisa-
tional settings (e.g. the extent to which networks
facilitate working across organisational and professional
boundaries). Our examination of the outcomes of the
centralisations (what works and at what cost) will be
grounded in our understanding of the planning and im-
plementation of the changes (‘how and why’).
Exploring generalisability to other contexts
Towards the end of this study, we will hold a stakeholder
workshop to share findings with policy makers, clinicians,
managers, patients and carers from a range of clinical set-
tings across England. Attendees will discuss how our find-
ings might apply to other contexts and how best to take
our lessons forward, e.g. identifying translational obstacles
and enablers.
Discussion
Through the DCE, this study will provide valuable insights
on key stakeholders’ priorities in relation to changes of this
kind. We will present an analysis of the impact of these
centralisations on care provision, clinical outcomes, cost-
effectiveness and patient experience. However, such find-
ings alone are of limited benefit, as they leave unanswered
the important questions of how impacts were achieved (or
not) and which factors were influential. We will conduct
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in-depth qualitative analysis of how the new models of care
were planned and implemented, and their impact, using a
framework identifying key components of major system
change developed in previous research on acute stroke ser-
vice centralisation [31]. We will test and develop this
framework in a different healthcare context and contribute
to understanding of how networks operate across complex
organisational settings and influence major system change.
Our focus on contextual factors will support generalisability
beyond the specialist cancer surgery settings studied. We
will thus generate lessons for potential future centralisa-
tions of specialist services, in terms of engaging key stake-
holders, planning and implementing change, and potential
impact on quality and outcomes of care.
This study faces a number of challenges. For the DCE,
we require at least 400 responses, covering patients,
healthcare professionals and the public. To maximise re-
sponses, we will publicise the survey actively and work
with Quality Health (who runs the NCPES) to obtain a
balanced sample in a manner that does not threaten pa-
tient privacy.
Certain aspects of the qualitative analysis, especially in
relation to London Cancer, will be retrospective. We
have addressed this issue by careful stakeholder sam-
pling and collecting contemporaneous documentation.
The relative recency of the London changes means the
centralisations remain a relevant issue.
For the analysis of outcomes, an issue relates to the dis-
tinction between primary and secondary outcome mea-
sures. As noted, the primary outcomes used to power the
analysis were selected with clinician team members, though
other measures were also identified as important. While we
recognise the value of primary outcomes in demonstrating
feasibility and usefulness of the analysis, we will analyse a
range of outcome measures and consider the distinction
between ‘primary’ and ‘secondary’ measures somewhat arbi-
trary. Secondly, a practical challenge will be assembling and
analysing the data in a timely manner, especially for Man-
chester Cancer as the changes there have yet to occur. This
will also affect the cost-effectiveness analysis, which de-
pends on data and results from this quantitative analysis.
Further, the cost-effectiveness analysis might encoun-
ter difficulties in obtaining accurate information on the
time people spent working on the centralisations. This is
common to many implementation studies, as people find
it hard to quantify exactly the time they dedicate to a
particular project, given overlap with other projects or
day-to-day working. However, evaluating the changes in
real-time and collecting data prospectively increases the
likelihood of our obtaining these data.
There are significant drives to centralise healthcare ser-
vices, but the evidence available in relation to such changes
is limited. This study will generate important lessons—in
terms of stakeholder preferences for centralisations, how
change is planned and implemented and its impact on care
provision, clinical outcomes and costs—that will be of value
to planners of service centralisation, both in the English
NHS and internationally.
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